5α-dihydrotestosterone inhibits Iα,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells

被引:14
作者
Lou, YR [1 ]
Nazarova, N
Talonpoika, R
Tuohimaa, P
机构
[1] Tampere Univ, Dept Anat, Sch Med, FIN-33014 Tampere, Finland
[2] Tampere Univ Hosp, Dept Clin Chem, FIN-33521 Tampere, Finland
关键词
25-hydroxyvitamin D-3 24-hydroxylase; I alpha; 25-dihydroxyvitamin D-3; androgen receptor; DHT; LNCaP; prostate cancer;
D O I
10.1002/pros.20189
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. A cross-talk between la,25-dihydroxyvitamin D-3 [1 alpha.,25-(OH)(2)D-3] and 5 alpha-dihydrotestosterone (DHT) in the growth inhibition has been demonstrated, but the mechanism is unknown. METHODS. The expression of 25-hydroxyvitamin D-3 24-hydroxylase (24-hydroxylase) was measured using a real-time quantitative RT-PCR assay and the catabolism of 1 alpha,25-(OH)(2)D-3 was measured using a radioreceptor assay. RESULTS. Real-time RT-PCR showed that DHT at 1-100 nM significantly inhibited 1 alpha,25-(OH)(2)D-3-induced expression of 24-hydroxylase in LNCaP cells. Furthermore, the catabolism of 1 alpha,25-(OH)(2)D-3 was decreased by 10 nM DHT. An androgen receptor (AR) antagonist, Casodex antagonized the DHT effect, whereas an AR agonist (due to the mutant AR in LNCaP cells) hydroxyflutamide did not. CONCLUSIONS. We demonstrated, for the first time, that DHT reduces the ability of 1 alpha,25-(OH)(2)D-3 to induce 24-hydroxylase expression. Our results not only support the earlier finding of a cross-talk between androgen and vitamin D in human prostate cancer cells but also provide a possible mechanism how androgen and vitamin D signaling pathways may interact. (c) 2004 Wiley-Liss. Inc.
引用
收藏
页码:222 / 230
页数:9
相关论文
共 44 条
[21]   25-hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells [J].
Lou, YR ;
Laaksi, I ;
Syvälä, H ;
Bläuer, M ;
Tammela, TLJ ;
Ylikomi, T ;
Tuohimaa, P .
FASEB JOURNAL, 2003, 17 (15) :332-+
[22]  
LUCIA MS, 1995, CANCER RES, V55, P5621
[23]   Liarozole acts synergistically with 1α,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity [J].
Ly, LH ;
Zhao, XY ;
Holloway, L ;
Feldman, D .
ENDOCRINOLOGY, 1999, 140 (05) :2071-2076
[24]   1α,25-dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo [J].
Mantell, DJ ;
Owens, PE ;
Bundred, NJ ;
Mawer, EB ;
Canfield, AE .
CIRCULATION RESEARCH, 2000, 87 (03) :214-220
[25]   STEROID-HORMONE RECEPTORS COMPETE FOR FACTORS THAT MEDIATE THEIR ENHANCER FUNCTION [J].
MEYER, ME ;
GRONEMEYER, H ;
TURCOTTE, B ;
BOCQUEL, MT ;
TASSET, D ;
CHAMBON, P .
CELL, 1989, 57 (03) :433-442
[26]   Role of 24-hydroxylase in vitamin D3 growth response of OVCAR-3 ovarian cancer cells [J].
Miettinen, S ;
Ahonen, MH ;
Lou, YR ;
Manninen, T ;
Tuohimaa, P ;
Syvälä, H ;
Ylikomi, T .
INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (03) :367-373
[27]  
MILLER GJ, 1992, CANCER RES, V52, P515
[28]  
Miller GJ, 1995, CLIN CANCER RES, V1, P997
[29]  
PEEHL DM, 1994, CANCER RES, V54, P805
[30]  
Prehn RT, 1999, CANCER RES, V59, P4161